Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Imperial College London |
---|---|
Information provided by: | Imperial College London |
ClinicalTrials.gov Identifier: | NCT00147069 |
The aim of this study is to examine the inflammatory mechanisms involved in the pathogenesis of inflammatory lung disease, in particular to compare the inflammatory profile seen in asthma and COPD. Evidence for inflammation in asthma and COPD is based on the finding of increased numbers of macrophages and neutrophils in the lungs and respiratory secretions of these patients. The inflammatory cells produce proteases, as well as, reactive oxidant species resulting in a protease/anti-protease imbalance which favours lung destruction. The aim is to examine the inflammatory mediators released by inflammatory cells (such as, macrophages and lymphocytes) in order to determine whether there are differences between non-smoking subjects, smoking subjects and patients with asthma or COPD. Monocytes are precursors of alveolar macrophages, and both monocytes and neutrophils are recruited to the lung from the blood via the action of specific chemoattractants. We have evidence that in inflammation there are higher levels of these chemoattractants. Therefore these cells might also demonstrate the same changes seen in alveolar macrophages from these patients.
We also aim to assess the role of the macrophage precursor (monocyte) and neutrophils in the blood. We will also assess lymphocyte/monocyte interaction. We will do this as the lymphocyte may be involved in the initial recruitment of inflammatory cells. We will also assess the role of cytokines involved with monocyte/macrophage/neutrophil migration in induced sputum as well as the role of induced sputum in the migration of monocytes and neutrophils into the lung. Our aim is to link the initial changes in blood to the changes causing disease in the lungs. We aim to examine cellular responses in four groups of subjects, namely (i) non-smoking controls, (ii) smokers without clinical evidence of COPD or asthma, (iii) smokers with COPD (iv) asthmatic patients.
Condition |
---|
Asthma COPD Emphysema Chronic Bronchitis |
Study Type: | Observational |
Study Design: | Natural History, Cross-Sectional, Defined Population, Retrospective/Prospective Study |
Official Title: | Investigation Into Inflammatory Mechanisms in Airway Cells in Smokers and Non-Smokers With Inflammatory Lung Disease. |
Estimated Enrollment: | 90 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | April 2005 |
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Asthmatic patients:
COPD patients:
Normal Volunteers
Healthy Smokers 1. Age 21-79 years of both sexes (females will be taking adequate contraceptive measures ) 2. Smokers 3. Normal lung function 4. No upper respiratory tract infection within the last 4 weeks
-
Exclusion Criteria:
COPD patients:
1. Any other active lung diseases 2. Upper respiratory infection within the last 4 weeks 3. Pregnancy or breast feeding 4. Any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study 5. Subjects unable to give informed consent
-
Contact: Louise E Donnelly, PhD | 0207 352 8121 ext 3061 | l.donnelly@imperial.ac.uk |
United Kingdom | |
Royal Brompton Hospital/NHLI Imperial College London | Recruiting |
London, United Kingdom, SW3 6LY | |
Contact: Louise E Donnelly, PhD 0207 352 8121 ext 3061 l.donnelly@imperial.ac.uk |
Principal Investigator: | Louise E Donnelly, PhD | Imperial College London |
Study ID Numbers: | 04-059 |
Study First Received: | September 6, 2005 |
Last Updated: | September 6, 2005 |
ClinicalTrials.gov Identifier: | NCT00147069 |
Health Authority: | United Kingdom: Research Ethics Committee |
sputum macrophage neutrophil |
Emphysema Asthma Pulmonary Emphysema Bronchitis, Chronic Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases |
Respiratory Tract Infections Lung Diseases Hypersensitivity, Immediate Bronchitis Respiratory Hypersensitivity Pulmonary Disease, Chronic Obstructive |
Pathologic Processes Immune System Diseases Bronchial Diseases |